Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 7,852 matching trials from the live ClinicalTrials.gov search.
Filters: Minneapolis, Minnesota Clear all
Recruiting No phase listed Observational

Molecular Epidemiology of Pediatric Germ Cell Tumors

NCT05564026
View directory record Official record
Conditions
Germ Cell Tumor, Germinoma, Teratoma, Embryonal Carcinoma, Yolk Sac Tumor, Choriocarcinoma, Mixed Germ Cell Tumor, Late Effects, Pediatric Germ Cell Tumor
Interventions
Questionnaire Administration, Tumor Specimen Collection, Germline DNA Samples, Blood Sample Collection
Other · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
1,151 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Phase 2 Interventional

A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

NCT02092935
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
SMT19969, Vancomycin
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
24
States / cities
Mobile, Alabama • Laguna Hills, California • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia

NCT02282215
View directory record Official record
Conditions
Acute Myeloid Leukemia, Neutropenia, Infection
Interventions
CLT-008, G-CSF
Biological
Lead sponsor
Cellerant Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Not applicable Interventional

Facilitating Shared Decisionmaking About Prostate Cancer Screening

NCT00013247
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate Cancer Screening Education
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years and older · Male only
Enrollment
1,152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Phase 2Phase 3 Interventional

Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)

NCT01782989
View directory record Official record
Conditions
Geographic Atrophy
Interventions
ORACEA®, Placebo
Drug
Lead sponsor
Paul Yates, MD, PhD
Other
Eligibility
55 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
37
States / cities
Glendale, California • Poway, California • Golden, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 31, 2026, 5:37 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Remote Trial - Tobacco Product Standard (VLNC)

NCT06442384
View directory record Official record
Conditions
Tobacco Use
Interventions
Tobacco and non-tobacco e-cigarettes, Tobacco only e-cigarettes
Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

NCT02597933
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Nintedanib, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

NCT00844649
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Albumin-bound paclitaxel (ABI-007), Gemcitabine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 79 Years
Enrollment
861 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
90
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Phase 1 Interventional

Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

NCT00138216
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, temozolomide, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Orange, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Not applicable Interventional

Morning Versus Evening Dosing of Antihypertensive Medications: A Pilot Study to Assess Feasibility and Efficacy

NCT01965847
View directory record Official record
Conditions
Hypertension
Interventions
Medication therapy management
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
19 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 31, 2026, 5:37 PM EDT
Terminated Phase 2 Interventional Results available

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

NCT04191135
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Pembrolizumab, Olaparib, Carboplatin, Gemcitabine
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
25
States / cities
Monterey, California • San Francisco, California • Santa Monica, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 31, 2026, 5:37 PM EDT
Terminated Not applicable Interventional Results available

Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED-HED) Study

NCT02481206
View directory record Official record
Conditions
Sudden Cardiac Death, Sudden Cardiac Arrest
Interventions
Wearable Cardioverter Defibrillator
Device
Lead sponsor
Zoll Medical Corporation
Industry
Eligibility
50 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
31
States / cities
Corona, California • Downey, California • Escondido, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection

NCT00917852
View directory record Official record
Conditions
Thoracic Injuries
Interventions
Gore Conformable TAG Thoracic Endoprosthesis
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT00006008
View directory record Official record
Conditions
Leukemia
Interventions
arsenic trioxide
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
68
States / cities
Scottsdale, Arizona • Duarte, California • Palo Alto, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 31, 2026, 5:37 PM EDT
Completed No phase listed Observational

Genetic Evaluation of NF1 and Scoliosis Patients

NCT01776125
View directory record Official record
Conditions
Neurofibromatosis 1, Scoliosis
Interventions
Cheek swab
Other
Lead sponsor
University of Minnesota
Other
Eligibility
6 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Phase 3 Interventional

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

NCT04538625
View directory record Official record
Conditions
Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, Adult Solid Tumor, Prophylaxis of Diarrhea, Symptomatic Relief of Diarrhea, Targeted Therapy-related Diarrhea
Interventions
Crofelemer 125 MG [Mytesi], Placebo
Drug
Lead sponsor
Napo Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
27
States / cities
Prescott, Arizona • Anaheim, California • Corona, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 31, 2026, 5:37 PM EDT
Recruiting Not applicable Interventional

Home-based Rehabilitation Intervention for Phantom Limb Pain in Veterans With Lower Limb Amputations

NCT06106984
View directory record Official record
Conditions
Phantom Limb Pain
Interventions
Graded motor imagery mobile app
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Phase 4 Interventional Results available

Propofol Versus Alfentanil Versus Nitrous Oxide for Moderate Procedural Sedation

NCT00997126
View directory record Official record
Conditions
Sedation
Interventions
Propofol, Alfentanil
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

NCT02591615
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
MK-3475, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
La Jolla, California • Chicago, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Phase 3 Interventional Results available

Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)

NCT00406393
View directory record Official record
Conditions
Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic, Myelodysplastic Syndromes
Interventions
Tacrolimus, Methotrexate, Sirolimus
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 60 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
23
States / cities
Duarte, California • La Jolla, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 31, 2026, 5:37 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521
View directory record Official record
Conditions
PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions
Zovegalisib, Capivasertib, Fulvestrant
Drug
Lead sponsor
Relay Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
52
States / cities
Gilbert, Arizona • Beverly Hills, California • Duarte, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Phase 4 Interventional

An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS

NCT00206648
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Betaferon/Betaseron
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
51
States / cities
Tucson, Arizona • Berkeley, California • Irvine, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Oct 31, 2026, 5:37 PM EDT
Not listed Not applicable Interventional

N-Acetylcysteine for Patients With COPD and ChronicBronchitis

NCT01599884
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions
N-acetylcysteine, Oral acetylcysteine
Drug
Lead sponsor
Center for Veterans Research and Education
Other
Eligibility
40 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 31, 2026, 5:37 PM EDT
Completed Phase 2 Interventional Results available

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

NCT00525148
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BIBW 2992
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 99 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
23
States / cities
Bakersfield, California • Beverly Hills, California • Mission Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 31, 2026, 5:37 PM EDT